<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741558</url>
  </required_header>
  <id_info>
    <org_study_id>UP 4747/12</org_study_id>
    <secondary_id>CAAE 04482712.3.0000.5333</secondary_id>
    <nct_id>NCT01741558</nct_id>
  </id_info>
  <brief_title>The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial InfarctionS (TETHYS Trial)</brief_title>
  <acronym>TETHYS</acronym>
  <official_title>The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial InfarctionS: Randomized Double-blind, Placebo-controlled Trial (TETHYS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiologia do Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Cardiologia de Santa Catarina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Cardiologia do Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental studies suggest that anti-inflammatory and immunomodulatory drugs could reduce
      the inflammatory profile in acute ischemic disease and reduce the area of ischemia.
      Methotrexate is a drug that has shown promise in ischemic disease in animal studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis and ischemic disease have clear association with inflammation. There is an
      anti-inflammatory action of methotrexate by increasing adenosine. Experimental studies
      demonstrate reduction of infarct induced in animals treated with methotrexate. We expect a
      reduction in the area under the curve of creatine kinase (CK), creatine kinase MB fraction
      (CK-MB) and Troponin I high sensitive, decreased levels of B-type natriuretic peptide (BNP)
      and improvement in left ventricular ejection fraction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of creatine kinase</measure>
    <time_frame>During 72 hours after the infarct</time_frame>
    <description>The primary end point was the reduction of the size of the infarct as assessed by the area under the curve (AUC) (expressed in arbitrary units) for creatine kinase (CK) during 72 hours after the infarct</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for creatine kinase MB fraction and troponin I high sensitive</measure>
    <time_frame>During 72 hours after the infarct</time_frame>
    <description>The primary end point was the reduction of the size of the infarct as assessed by the area under the curve (AUC) (expressed in arbitrary units) for creatine kinase MB fraction(CK-MB) and Troponin I high sensitive during 72 hours after the infarct</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the peaks of CK, CK-MB and troponin I ultra-sensitive</measure>
    <time_frame>During 72 hours after the infarct</time_frame>
    <description>Compare the peaks of CK, CK-MB and troponin I ultra-sensitive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the levels of high-sensitivity C-reactive protein at admission, after 72 hours and after 3 months</measure>
    <time_frame>After 72 hours and after 3 months</time_frame>
    <description>Compare the levels of high-sensitivity C-reactive at admission, after 72 hours and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the levels of erythrocyte sedimentation rate on admission and after 72 hours</measure>
    <time_frame>On admission and after 72 hours</time_frame>
    <description>Compare the levels of erythrocyte sedimentation rate on admission and after 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare B-type natriuretic peptide (BNP) levels on admission, after 72 hours and after 3 months</measure>
    <time_frame>On admission, after 72 hours and after 3 months</time_frame>
    <description>Compare B-type natriuretic peptide (BNP) levels on admission, after 72 hours and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the &quot;TIMI frame count&quot; of the culprit artery</measure>
    <time_frame>On admission</time_frame>
    <description>Compare the &quot;TIMI frame count&quot; of the culprit artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the Killip score on admission and after 72 hours</measure>
    <time_frame>On admission and after 72 hours</time_frame>
    <description>Compare the Killip score on admission and after 72 hours;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess ventricular ejection fraction with transthoracic echocardiography during the first 72 hours after 3 months</measure>
    <time_frame>During the first 72 hours after 3 months</time_frame>
    <description>Assess ventricular ejection fraction with transthoracic echocardiography during the first 72 hours after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess mortality at 3 months</measure>
    <time_frame>At 3 months;</time_frame>
    <description>Assess mortality at 3 months;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate reinfarction in 3 months</measure>
    <time_frame>In 3 months</time_frame>
    <description>Evaluate reinfarction in 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate side effects</measure>
    <time_frame>In 72 hours</time_frame>
    <description>Evaluation in 72 hours the changes in the levels of hematocrit, hemoglobin, leukocytes and platelets, changes in the levels of serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase and prothrombin Time; changes in the levels of plasma creatinine, gastrointestinal effects (oral ulcers, diarrhea, nausea and vomiting), skin changes (rash, pruritus, and alopecia) and pulmonary effects (pneumonitis and pneumonia).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Established treatment associated with methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Riboflavin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>Rheumatrex®</other_name>
    <other_name>Trexall®</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.</description>
    <arm_group_label>Placebo (Riboflavin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years;

          -  Chest pain suggestive of acute myocardial infarction initiated within 12 hours;

          -  Electrocardiogram with ST-segment elevation greater than or equal to 0.2 mV in at
             least 2 contiguous leads;

          -  Choice of primary angioplasty

        Exclusion Criteria:

          -  Prior acute myocardial infarction;

          -  Prior heart failure;

          -  Angioplasty in the last 3 months;

          -  Cardiac arrest or cardiogenic shock;

          -  History of renal insufficiency (serum creatinine greater than 2.0 mg/dl);

          -  History of alcohol abuse (consumption equal to or greater than 20 drinks per week);

          -  Illicit drug use;

          -  Evidence of rheumatoid arthritis;

          -  Neoplasia;

          -  Infectious diseases;

          -  Prior anemia (hematocrit below 30%);

          -  Use of anti-inflammatory hormonal or non-hormonal last week;

          -  Xanthines excessive consumption (more than two and a half cups of coffee or two and a
             half mate gourds);

          -  Pregnancy;

          -  Disagreement with the term of consent;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M. Moreira, MD. MSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Cardiologia do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel M. Moreira, MD. MSc</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel M. Moreira, MD. MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Cardiologia do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos AM Gottschall, MD MSc PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria E. Lueneberg, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia de Santa Catarina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto L. da Silva, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia de Santa Catarina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tammuz Fattah, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia de Santa Catarina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel M. Moreira, MSc.</last_name>
    <phone>554884175590</phone>
    <email>danielmedeirosmoreira@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Rio Grande do Sul / Fundação Universitária de Cardiologia</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90620001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel M. Moreira, MD. MSc.</last_name>
      <phone>554884175590</phone>
      <email>danielmedeirosmoreira@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel M. Moreira, MD. MSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos AM Gottschall, MD MSc PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia de Santa Catarina</name>
      <address>
        <city>São José</city>
        <state>Santa Catarina</state>
        <zip>88103901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel M. Moreira, MD. MSc</last_name>
      <phone>554884175590</phone>
      <email>danielmedeirosmoreira@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria E. Lueneberg, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel M. Moreira, MD. MSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto L. da Silva, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tammuz Fattah, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Inflammation Mediators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

